シスプラチン起因性腎障害の予防薬の同定

• Published in: 日本薬理学会年会要旨集 p. 2-O-D3-1
• Main Authors: 池田, 康将, 濱野, 裕章, 合田, 光寛, 福島, 圭穰, 岸, 誠司, 中馬, 真幸, 座間味, 義人, 宮本, 理人, 石澤, 啓介, 藤野, 裕道, 粟飯原, 賢一, 土屋, 浩一郎, 玉置, 俊晃
• Format: Journal Article
• Language: Japanese
• Published: 公益社団法人 日本薬理学会 2021
• Subjects: kidney
• ISSN: 2435-4953
• DOI: 10.1254/jpssuppl.94.0_2-O-D3-1

Background: Cisplatin is widely used as an anti-tumor drug for the treatment of solid tumors. Unfortunately, it causes nephrotoxicity as a critical side effect, limiting its use, given that no preventive drug against cisplatin-induced nephrotoxicity (CIN) is currently available. In the present study, we searched and identified candidate drugs for preventing CINMethods: We used a database of medical big data for the screening of candidate drugs for the prevention of CIN. Based on the results of the analysis of medical big data, we evaluated the actual efficacy of DPH via in vitro and in vivo experiments in culture cells and a mouse model.Results: We identified that a previously developed drug, diphenhydramine (DPH), may provide a novel treatment for CIN by the analysis of medical big data. DPH inhibited cisplatin-induced cell death in renal proximal tubular cells. Mice administered cisplatin developed kidney injury with renal dysfunction, augmented oxidative stress, increased apoptosis, and elevated inflammatory cytokines; however, most of these symptoms were suppressed by treatment with DPH. Additionally, the renal concentration of cisplatin was attenuated in DPH-treated mice. Importantly, DPH did not i interfere with its anti-tumor effect in any of the in vitro or in vivo experiments. Moreover, a retrospective clinical study showed that patients with malignant cancer who had used DPH before cisplatin treatment exhibited less acute kidney injury. Conclusion: DPH may be a preventive medicine against CIN.